BRPI0412194A - composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida - Google Patents
composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólidaInfo
- Publication number
- BRPI0412194A BRPI0412194A BRPI0412194-5A BRPI0412194A BRPI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A
- Authority
- BR
- Brazil
- Prior art keywords
- dog
- cird
- antibody
- composition
- immune response
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 title abstract 3
- 241000282465 Canis Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002458 infectious effect Effects 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000606161 Chlamydia Species 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 239000003547 immunosorbent Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000007790 solid phase Substances 0.000 title 1
- 241000894007 species Species 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 239000000758 substrate Substances 0.000 title 1
- 241000694560 Mycoplasma cynos Species 0.000 abstract 6
- 241000282472 Canis lupus familiaris Species 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"COMPOSIçãO, MéTODOS PARA VACINAR UM CãO CONTRA DOENçA RESPIRATóRIA INFECCIOSA CANINA, PARA TRATAR CIRD EM UM CãO, PARA ESTIMULAR UMA RESPOSTA IMUNE, PARA PREPARAR E OBTER UM ANTICORPO, PARA IMUNIZAR PASSIVAMENTE UM CãO CONTRA CIRD, E PARA DETERMINAR SE UM CãO FOI EXPOSTO A UMA ESPéCIE DE CHLAMYDOPHILA ASSOCIADA COM CIRD, OU SE UM CãO APRESENTA, OU é SUSCETìVEL A CIRD, USOS DE QUALQUER UM OU MAIS AGENTES, E DE ANTICORPOS, KIT DE PARTES PARA UMA COMPOSIçãO DE VACINA, ANTICORPO, ENSAIO IMUNOSSORVENTE, E, SUBSTRATO DE FASE SOLIDA". Uma composição de vacina para vacinar cães compreendendo qualquer um ou mais de (a) um agente capaz de suscitar uma resposta imunológica contra Streptococcus equi subespécie zooepidedemicus em um cão. (b) um agente capaz de suscitar uma resposta imunológica contra Mycoplasma cynos em um cão, e (c) um agente capaz de suscitar uma resposta imunológica contra um Chlamydophila em um cão.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0315323.6A GB0315323D0 (en) | 2003-07-01 | 2003-07-01 | Vaccine composition |
| PCT/GB2004/002865 WO2005002618A1 (en) | 2003-07-01 | 2004-07-01 | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412194A true BRPI0412194A (pt) | 2006-08-22 |
Family
ID=27676393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412194-5A BRPI0412194A (pt) | 2003-07-01 | 2004-07-01 | composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8329194B2 (pt) |
| EP (2) | EP2050463B1 (pt) |
| JP (1) | JP5698890B2 (pt) |
| KR (1) | KR20060106809A (pt) |
| CN (1) | CN1845754A (pt) |
| AT (1) | ATE442857T1 (pt) |
| AU (1) | AU2004253344B2 (pt) |
| BR (1) | BRPI0412194A (pt) |
| CA (1) | CA2530797C (pt) |
| DE (1) | DE602004023196D1 (pt) |
| DK (1) | DK2050463T3 (pt) |
| ES (2) | ES2356396T3 (pt) |
| GB (1) | GB0315323D0 (pt) |
| MX (1) | MXPA06000278A (pt) |
| NO (1) | NO20056207L (pt) |
| NZ (1) | NZ544453A (pt) |
| PT (1) | PT2050463E (pt) |
| RU (1) | RU2006102863A (pt) |
| WO (1) | WO2005002618A1 (pt) |
| ZA (1) | ZA200600918B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| CN100388952C (zh) * | 2006-04-25 | 2008-05-21 | 范红结 | 一种链球菌重组亚单位疫苗及其制备方法 |
| UA99719C2 (ru) * | 2006-11-03 | 2012-09-25 | Шеринг-Плау Лтд. | Вакцина для собак против болезни лайма |
| WO2011112593A1 (en) * | 2010-03-10 | 2011-09-15 | Intervet International B.V. | Method for protecting against disease caused by secondary pathogens |
| PL2670432T3 (pl) | 2011-02-04 | 2021-10-11 | Zoetis Services Llc | Kompozycje immunogenne Bordetella bronchiseptica |
| CA2826058C (en) | 2011-02-04 | 2017-06-06 | Zoetis Llc | Compositions for canine respiratory disease complex |
| EP2854847B1 (en) | 2012-05-31 | 2019-08-07 | Zoetis Services LLC | Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections |
| CN111499702B (zh) * | 2020-05-07 | 2021-04-06 | 山东畜牧兽医职业学院 | 一种马链球菌兽疫亚种的检测试剂盒及检测方法 |
| MX2023003961A (es) * | 2020-10-08 | 2023-06-02 | Controlpoint Inc | Metodos y aparatos para detectar infecciones respiratorias. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4567042A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| US4567043A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
| GB8426468D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| GB8517895D0 (en) | 1985-07-16 | 1985-08-21 | Technology Licence Co Ltd | Monoclonal antibodies |
| ATE71303T1 (de) | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
| US4944972A (en) * | 1987-12-31 | 1990-07-31 | American National Can Company | Coextrusion apparatus, methods, and related films and packages |
| US5672350A (en) | 1989-08-22 | 1997-09-30 | Veterinary Infectious Disease Organization | Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines |
| GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US5583014A (en) * | 1990-07-03 | 1996-12-10 | Bayer Corporation | Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine |
| US6057436A (en) | 1990-11-14 | 2000-05-02 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
| NZ240558A (en) | 1990-11-14 | 1994-11-25 | Smithkline Beecham Corp | Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease |
| US6372224B1 (en) | 1990-11-14 | 2002-04-16 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
| ES2213743T3 (es) | 1991-04-25 | 2004-09-01 | Akzo Nobel N.V. | Vacuna de subunidad de coronavirus canino. |
| DE4134297A1 (de) * | 1991-10-17 | 1993-04-22 | Behringwerke Ag | Monoclonale antikoerper gegen mycoplasma pneumoniae, diese produzierende hybridome, verfahren zu deren herstellung sowie deren verwendung |
| ES2182827T3 (es) | 1992-05-08 | 2003-03-16 | Pfizer | Gen del virus corona canino y usos del mismo. |
| US5750112A (en) | 1993-02-26 | 1998-05-12 | Solvay Animal Health, Inc. | Canine coronavirus vaccine from feline enteric coronavirus |
| CA2183684C (en) * | 1994-02-18 | 2008-07-15 | Richard D. Hansen | Inoculation of animals with dried, pelleted biological materials |
| WO1996041874A1 (en) | 1995-06-12 | 1996-12-27 | Kansas State University Research Foundation | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection |
| US5753235A (en) * | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
| WO1998016643A1 (en) | 1996-10-11 | 1998-04-23 | Human Genome Sciences, Inc. | Brain-associated inhibitor of tissue-type plasminogen activator |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US6682745B1 (en) * | 1998-07-28 | 2004-01-27 | Christiaan Antonius Arnoldus Jacobs | Use of bacterium for manufacture of a vaccine |
| WO1999025838A1 (en) | 1997-11-14 | 1999-05-27 | University Of Georgia Research Foundation, Inc. | Compositions and methods to prevent turkey enteritis |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| EP1023903B1 (en) | 1999-01-26 | 2004-01-14 | Akzo Nobel N.V. | Use of life attenuated bacteria for the manufacture of a submucosal vaccine |
| US20010048927A1 (en) * | 2000-02-01 | 2001-12-06 | Richard Stephens | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia |
| US6548069B2 (en) * | 2001-02-03 | 2003-04-15 | Hmv Associates, Inc. | Multivalent Mycoplasma bacterin |
| WO2003018051A1 (en) * | 2001-08-27 | 2003-03-06 | Vic Jira | Anti-fungal composition |
| GB0217434D0 (en) * | 2002-07-27 | 2002-09-04 | Royal Vetinary College | Biological material |
| US8404245B2 (en) | 2002-10-11 | 2013-03-26 | Intervacc Ab | Immunization of non-human mammals against Streptococcus equi |
| US7793433B2 (en) * | 2006-07-14 | 2010-09-14 | Footbalance System Oy | Individually formed footwear and a related method |
-
2003
- 2003-07-01 GB GBGB0315323.6A patent/GB0315323D0/en not_active Ceased
-
2004
- 2004-07-01 ES ES04743211T patent/ES2356396T3/es not_active Expired - Lifetime
- 2004-07-01 MX MXPA06000278A patent/MXPA06000278A/es unknown
- 2004-07-01 ES ES08075914T patent/ES2432175T3/es not_active Expired - Lifetime
- 2004-07-01 NZ NZ544453A patent/NZ544453A/xx not_active IP Right Cessation
- 2004-07-01 EP EP08075914.5A patent/EP2050463B1/en not_active Expired - Lifetime
- 2004-07-01 WO PCT/GB2004/002865 patent/WO2005002618A1/en not_active Ceased
- 2004-07-01 DE DE602004023196T patent/DE602004023196D1/de not_active Expired - Lifetime
- 2004-07-01 EP EP04743211A patent/EP1638599B1/en not_active Expired - Lifetime
- 2004-07-01 AU AU2004253344A patent/AU2004253344B2/en not_active Ceased
- 2004-07-01 US US10/563,199 patent/US8329194B2/en not_active Expired - Fee Related
- 2004-07-01 RU RU2006102863/15A patent/RU2006102863A/ru not_active Application Discontinuation
- 2004-07-01 BR BRPI0412194-5A patent/BRPI0412194A/pt not_active Application Discontinuation
- 2004-07-01 CN CNA2004800250016A patent/CN1845754A/zh active Pending
- 2004-07-01 CA CA2530797A patent/CA2530797C/en not_active Expired - Fee Related
- 2004-07-01 PT PT80759145T patent/PT2050463E/pt unknown
- 2004-07-01 AT AT04743211T patent/ATE442857T1/de not_active IP Right Cessation
- 2004-07-01 DK DK08075914.5T patent/DK2050463T3/da active
- 2004-07-01 KR KR1020067000080A patent/KR20060106809A/ko not_active Withdrawn
- 2004-07-01 JP JP2006518335A patent/JP5698890B2/ja not_active Expired - Fee Related
-
2005
- 2005-12-27 NO NO20056207A patent/NO20056207L/no not_active Application Discontinuation
-
2006
- 2006-01-31 ZA ZA200600918A patent/ZA200600918B/en unknown
-
2007
- 2007-09-04 US US11/849,931 patent/US20080220018A1/en not_active Abandoned
-
2010
- 2010-06-15 US US12/816,214 patent/US20110059128A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2050463T3 (da) | 2013-09-02 |
| US20070098739A1 (en) | 2007-05-03 |
| ES2432175T3 (es) | 2013-12-02 |
| US20110059128A1 (en) | 2011-03-10 |
| ES2356396T3 (es) | 2011-04-07 |
| EP2050463A3 (en) | 2010-01-20 |
| WO2005002618A1 (en) | 2005-01-13 |
| ATE442857T1 (de) | 2009-10-15 |
| US20080220018A1 (en) | 2008-09-11 |
| PT2050463E (pt) | 2013-10-29 |
| ZA200600918B (en) | 2007-07-25 |
| NO20056207L (no) | 2006-01-31 |
| NZ544453A (en) | 2009-04-30 |
| GB0315323D0 (en) | 2003-08-06 |
| CA2530797C (en) | 2014-08-26 |
| US8329194B2 (en) | 2012-12-11 |
| MXPA06000278A (es) | 2006-04-07 |
| RU2006102863A (ru) | 2006-09-10 |
| CA2530797A1 (en) | 2005-01-13 |
| DE602004023196D1 (de) | 2009-10-29 |
| JP2007526884A (ja) | 2007-09-20 |
| AU2004253344A1 (en) | 2005-01-13 |
| KR20060106809A (ko) | 2006-10-12 |
| EP1638599A1 (en) | 2006-03-29 |
| CN1845754A (zh) | 2006-10-11 |
| EP2050463B1 (en) | 2013-08-21 |
| AU2004253344B2 (en) | 2010-04-29 |
| EP1638599B1 (en) | 2009-09-16 |
| JP5698890B2 (ja) | 2015-04-08 |
| EP2050463A2 (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lambert et al. | Can successful vaccines teach us how to induce efficient protective immune responses? | |
| Mohebali et al. | Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, IR Iran | |
| Dhungyel et al. | Footrot vaccines and vaccination | |
| AR072378A1 (es) | Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos. | |
| PA8549701A1 (es) | Vacunacion en dosis unica con mycoplasma hyopneumoniae | |
| BRPI0412194A (pt) | composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida | |
| PA8549801A1 (es) | Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales | |
| BR112021020777A2 (pt) | Vacina de subunidade do csfv | |
| Newton et al. | Risk factors for equine influenza serum antibody titres in young Thoroughbred racehorses given an inactivated vaccine | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| Hodgins et al. | Influence of age and maternal antibodies on antibody responses of neonatal piglets vaccinated against Mycoplasma hyopneumoniae | |
| Yakobson et al. | Cattle rabies vaccination—a longitudinal study of rabies antibody titres in an Israeli dairy herd | |
| Jayashi et al. | Characterisation of antibody responses in pigs induced by recombinant oncosphere antigens from Taenia solium | |
| Malerczyk et al. | Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine | |
| Oreskovic et al. | Oil-based adjuvants delivered intradermally induce high primary IgG2 immune response in swine | |
| Suárez et al. | Evaluation of a Cooperia oncophora double-domain ASP-based vaccine against Cooperia spp. infections in cattle and sheep | |
| Fent et al. | Immunologic response to first booster vaccination in dogs treated with zenrelia™(ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls | |
| Cabasso et al. | Further Evidence of Immunologic Dissimilarity of Distemper (CD) and Measles (M) Viruses. | |
| BR0208980A (pt) | Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses | |
| Ikematsu et al. | Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan | |
| Servat et al. | Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model | |
| MacDonald et al. | Efficacy of a single dose hepatitis B depot vaccine | |
| CN110507819B (zh) | 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用 | |
| Çokçalışkan et al. | Booster administration can make a difference in the antibody response to intradermal foot-and-mouth disease vaccination in cattle | |
| Bharati et al. | DNA vaccines: Getting closer to becoming a reality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |